deaths (OS)progression or deaths (PFS)RFS/DFS

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus BSC
durvalumab plus tremelimumab vs. BSC 1 1.0better0.35.099 %1.0better0.35.053 %-